Automation in Biopharma Industry Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Technology (Automation Technology, Digitization Technology), By Application (Clinical Phase, Drug Discovery Phase, Production Phase), by Component (Automation Hardware, Automation Software, Services Project Phase, Services Operation Phase), by region, and Competition
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationAutomation in Biopharma Industry Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Technology (Automation Technology, Digitization Technology), By Application (Clinical Phase, Drug Discovery Phase, Production Phase), by Component (Automation Hardware, Automation Software, Services Project Phase, Services Operation Phase), by region, and Competition
Forecast Period | 2024-2028 |
Market Size (2022) | USD1775.20 million |
CAGR (2023-2028) | 5.80% |
Fastest Growing Segment | Digitization Technology |
Largest Market | North America |
Market Overview
Global Automation in Biopharma Industry Market was valued at USD 1775.20 million in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.80% through 2028. Automation in the biopharmaceutical (biopharma) industry refers to the use of advanced technology, systems, and processes to perform various tasks, experiments, and manufacturing processes with minimal human intervention. The primary goals of automation in the biopharma industry are to improve efficiency, accuracy, consistency, and safety in research, development, and manufacturing activities. In biopharmaceutical manufacturing, process automation is crucial. It involves the use of automated systems and instruments for tasks such as cell culture, fermentation, purification, and fill-finish operations. Process automation ensures the precise control of critical parameters (e.g., temperature, pH, and agitation) to maintain product quality and consistency. Robotic systems are employed for a wide range of tasks, from drug discovery and sample handling to filling and packaging in manufacturing. Robots can be programmed to handle samples, reagents, and labware, performing tasks with precision and repeatability.
Automation systems provide advanced quality control and assurance in biopharma manufacturing. They monitor and control critical parameters and offer real-time feedback to ensure that products meet stringent quality standards. The biopharma industry is subject to rigorous quality and safety regulations. Automation systems aid in compliance by providing accurate data, traceability, and documentation, which are crucial for regulatory approval. Ongoing technological innovations in automation, such as the use of artificial intelligence, machine learning, and robotics, are driving the adoption of cutting-edge systems for research and production. Biopharmaceutical products are becoming more complex, requiring advanced automation to produce biologics, cell therapies, and gene therapies.
Key Market Drivers
Technological Advancements
Robotics and automation have become increasingly sophisticated, with the integration of advanced robotics in laboratories and production facilities. These robots can perform a wide range of tasks, from liquid handling and sample preparation to cell culture maintenance. Automation systems have improved the efficiency of High-Throughput Screening (HTS) in drug discovery. Automated liquid handling and data analysis tools allow for the rapid screening of thousands of compounds for potential drug candidates. Lab-on-a-Chip (LOC) Technology integrates various laboratory functions onto a single chip, reducing the need for manual interventions. This technology is particularly useful for sample preparation and analysis. Advancements in software and data analytics enable real-time monitoring and analysis of experimental data. This facilitates quicker decision-making in drug development and manufacturing processes. Artificial Intelligence (AI) and Machine Learning (ML) are being used for data analysis, predictive modeling, and optimization of bioprocessing. They can help identify potential drug candidates and optimize manufacturing processes.
Process Analytical Technology (PAT) integrates sensors, process control, and data analysis to monitor and control bioprocesses in real time. This technology ensures product quality and consistency. Single-use bioreactors and disposable equipment have advanced, providing more cost-effective and flexible solutions for biopharma manufacturing. Continuous biopharma manufacturing processes are gaining traction. Automation enables continuous production of biologics, reducing the time and cost associated with batch manufacturing. Automated systems for quality control, including high-resolution imaging, mass spectrometry, and chromatography, improve product quality assurance and reduce the need for manual testing. Integrated automation platforms that combine various laboratory instruments, software, and data management systems provide a seamless workflow for biopharma researchers and manufacturers.
IoT-enabled devices and automation systems allow for remote monitoring and control of bioprocesses. This is especially valuable for ensuring consistent production and reducing the need for on-site presence. The use of nanotechnology in drug delivery and diagnostics has advanced. Automated systems can handle and analyze nanoparticles for various applications in biopharma. Automation has streamlined gene editing and CRISPR-Cas9 technologies, allowing for more precise and efficient genome editing for drug discovery and development. Automated bioprocessing systems are increasingly adaptable and customizable, allowing companies to tailor their systems to the specific needs of their products. Blockchain technology is being explored for secure data storage and sharing in the biopharma industry, ensuring the integrity and security of critical data. This factor will help in the development of the Global Automation in Biopharma Industry Market.
Increasing Complexity of Biopharmaceuticals
Biopharmaceuticals, such as monoclonal antibodies, gene therapies, and cell-based therapies, often involve intricate and multi-step manufacturing processes. Automation is essential to maintain precision and consistency throughout these complex processes. Complex biopharmaceuticals are subject to stringent regulatory requirements. Automation helps ensure compliance by providing accurate data, traceability, and documentation, which are crucial for regulatory approval. Complex biopharmaceuticals must meet exceptionally high-quality standards. Automation systems can consistently maintain product quality, ensuring that processes stay within the desired parameters and minimizing variability.
The complexity of biopharmaceutical production leaves room for errors in manual processes. Automation minimizes the influence of human error, which is crucial when dealing with complex and high-value biologics. Complex biopharmaceuticals generate large volumes of data. Automation facilitates data collection, storage, and analysis, enabling the handling of complex datasets and the extraction of valuable insights. The complexity of biopharmaceuticals necessitates continuous monitoring and control. Automation provides real-time monitoring of critical parameters, ensuring that the production process stays within the specified ranges. Many complex biopharmaceuticals need to be produced at various scales to meet market demand. Automation systems are designed to be scalable, allowing companies to adapt to changing production volumes.
Complex biopharmaceuticals are often high-value products, making the cost of errors or product loss significant. Automation minimizes the risk of errors and maximizes product yield. The trend toward personalized medicine, where treatments are customized for individual patients, involves the production of complex and patient-specific therapies. Automation helps tailor the manufacturing process for each patient, ensuring precision and consistency. Emerging biopharmaceuticals, including gene and cell therapies, are highly complex and innovative. Automation is essential to advance the development and production of these groundbreaking therapies. The market demand for complex biopharmaceuticals is on the rise due to the increasing prevalence of complex diseases and the need for more effective treatments. Automation is critical to meeting this demand efficiently. This factor will pace up the demand of Global Automation in Biopharma Industry Market.
Rising Demand of High-Throughput Screening
High-Throughput Screening (HTS) involves the rapid and automated testing of many compounds for various biological activities. HTS allows biopharmaceutical companies to test a vast library of compounds quickly. This accelerates the drug discovery process by identifying potential drug candidates in a fraction of the time it would take with manual testing. Automation in HTS reduces the cost per test, making it more economically feasible for biopharma companies to screen large numbers of compounds. This cost efficiency is vital for research and development budgets. HTS generates a significant amount of data in a short time. Automation enables efficient data collection and analysis, leading to the discovery of promising drug candidates and more precise drug development. The complexity of assays in biopharma research has increased as scientists seek to address more intricate biological questions. Automation is essential for handling these complex assays efficiently. Biopharma companies have access to extensive compound libraries. Automation is necessary to manage and screen these libraries effectively.
Automation is used in target identification and validation processes. HTS enables researchers to identify novel drug targets quickly, speeding up the early stages of drug discovery. After identifying potential drug candidates, HTS automation plays a crucial role in hit validation, where promising compounds are confirmed for their activity against specific targets. Automation enables the miniaturization of assays, reducing the number of reagents and compounds needed for testing. This not only saves costs but is also environmentally friendly. Automation systems ensure that screening assays are conducted consistently and with high precision, reducing the risk of experimental variability and errors.
Promising hits discovered through HTS can be scaled up for further research and development, ultimately leading to the production of biopharmaceuticals. Automation supports this scaling process. Automation is crucial for efficiently screening existing drugs for new therapeutic uses. This process, known as drug repurposing, can lead to the discovery of innovative treatments. HTS automation also plays a role in the safety assessment of potential drugs. It enables the testing of compounds for adverse effects and toxicity. Automation supports the discovery of targeted therapies that are tailored to specific diseases or patient populations. This is especially relevant in the era of personalized medicine. This factor will accelerate the demand of Global Automation in Biopharma Industry Market.
Key Market Challenges
Cost of Implementation
The purchase of automation equipment, software, and related technologies requires a substantial capital investment. This includes the costs of acquiring hardware, robotics, sensors, and other automation components. Tailoring automation systems to the specific needs of biopharmaceutical processes often involves customization. Custom solutions are typically more expensive than off-the-shelf products. Integrating automation systems with existing processes and infrastructure can be complex and costly. Compatibility and interoperability with legacy systems may require additional investments. Ensuring that automation systems meet regulatory standards and industry-specific validation requirements adds to the cost. Extensive testing, documentation, and validation processes are necessary to ensure compliance. Employees must be trained to operate and maintain automation systems effectively. Training programs come with associated costs, including staff time and external training resources. Automation systems require ongoing maintenance and technical support. This includes software updates, equipment maintenance, and troubleshooting, all of which have associated costs.
Maintaining Quality Assurance
Biopharmaceutical manufacturing processes can be intricate, involving multiple steps, and the complexity can make it challenging to maintain consistent product quality. Automation systems must be carefully designed and configured to ensure that every step is performed accurately. Variability can arise from various sources, including raw materials, environmental conditions, and equipment. Automation systems need to account for and minimize variability to ensure product consistency. The biopharma industry is subject to strict regulatory requirements. Maintaining compliance with Good Manufacturing Practices (GMP) and other regulations is a continuous challenge, as automation systems must adhere to these standards and provide documentation for audits and inspections. The validation of automated systems is a time-consuming and costly process. It is essential to validate automation systems thoroughly to ensure they consistently produce products of the desired quality. Automated instruments and sensors require regular calibration to maintain accuracy and reliability. Ensuring proper calibration is a critical aspect of quality assurance. In an automated environment, data integrity is essential. Automation systems must capture, store, and manage data accurately to support quality control and regulatory compliance. Automation systems must be designed to prevent cross-contamination of products or samples. This can be particularly challenging in multi-product manufacturing facilities.
Key Market Trends
Lab Automation
Lab automation systems enable high-throughput screening of compounds, allowing researchers to quickly test many potential drug candidates. This is essential in the early stages of drug discovery. Automation systems in the lab provide precise and accurate handling of samples, reducing the risk of human error and ensuring consistent and reliable results. Automation simplifies data collection, storage, and analysis. It enables real-time monitoring and data processing, facilitating faster decision-making in research and development. Automated processes are more efficient and can run continuously, reducing the time and effort required for experiments and assays. This accelerates research and development timelines. Automation reduces the need for manual labor in repetitive and time-consuming tasks, resulting in cost savings and the redeployment of human resources to more strategic activities. Automation optimizes the use of resources, such as reagents, consumables, and equipment, making laboratory operations more cost-effective.
Segmental Insights
Technology Insights
In 2022, the Global Automation in Biopharma Industry Market largest share was held by Digitization Technology segment and is predicted to continue expanding over the coming years.
Application Insights
In 2022, the Global Automation in Biopharma Industry Market largest share was held by Production Phase segment and is predicted to continue expanding over the coming years.
Component Insights
In 2022, the Global Automation in Biopharma Industry Market largest share was held by
Regional Insights
The North America region dominates the Global Automation in Biopharma Industry Market in 2022.
Recent Developments
- In February 2023, SiemensHealthineers, a prominent medical technology company, and Unilabs, a leadingprovider of diagnostic services, have jointly announced a multi-year agreementwith a value exceeding €200 million. Unilabs is making a substantial investmentin Siemens Healthineers' cutting-edge technology, acquiring more than 400laboratory analyzers to further enhance and upgrade its laboratoryinfrastructure. This strategic move is aimed at delivering an exceptional levelof service to its customers. Within the framework of this agreement, Unilabswill continue its ongoing efforts to modernize its healthcare infrastructureacross its network, with a primary focus on enhancing customer service andquality, ultimately leading to improved patient healthcare outcomes. Thesolutions provided by Siemens Healthineers will play a pivotal role inelevating Unilabs' laboratory operations, improving throughput, and ensuringclinical excellence throughout its testing network.
- In September 2022, PerkinElmer,Inc., a global leader in advancing innovations for a healthier world, hasintroduced the Cellaca PLX Image Cytometry System, a groundbreaking benchtopplatform designed to facilitate the assessment of multiple Critical QualityAttributes (CQAs) in cell samples through a single automated workflow. Thisincludes the evaluation of cell identity, quality, and quantity. Developed byPerkinElmer's Nexcelom unit, the state-of-the-art Cellaca PLX system integratescutting-edge image cytometer hardware, software, validated consumables, andtrackable data reporting, all within a user-friendly system that doesn'tnecessitate complex calibration procedures or extensive training. Additionally,the customer experience is further enhanced with optimized reagent kitscontaining validated antibodies from PerkinElmer's BioLegend division. Thisinnovative solution expands the capabilities for analysing cell sample CQAsbeyond traditional methods like flow cytometry and staining, which oftenrequire multiple instruments and complex analytical approaches. With thiscombined functionality, researchers can now simultaneously detect multiplemarkers (multiplexing) and conduct immunophenotyping and viability assaysquickly and effortlessly, thanks to the system's modern and intuitive userinterface.
Key Market Players
- PerkinElmer, Inc.
- AMETEK, Inc.
- Autodesk, Inc.
- Baumueller-Nuermont Corp
- Emerson Electric Co.
- Kawasaki Robotics
- RheoSense Inc.
- Rockwell Automation, Inc.
- Sartorius Stedim Biotech SA
- Siemens Healthineers
By Technology | By Application | By Component | By Region |
· Automation Technology · Digitization Technology | · Clinical Phase · Drug Discovery Phase · Production Phase | · Automation Hardware · Automation Software · Services Project Phase · Services Operation Phase | · North America · Asia-Pacific · Europe · South America · Middle East & Africa |
Table of Content
To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )
List Tables Figures
To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy